01 TAVR Makes Valve Replacement Less Invasive The aortic valve replacement market is shifting toward less invasive treatment as more patients become eligible for transcatheter aortic valve replacement (TAVR). Instead of opening the chest, TAVR allows doctors to place a replacement valve through a catheter. This can make treatment easier for selected patients and may reduce the recovery burden associated with open-heart surgery. Growing clinical evidence and improvements in valve technology are supporting aortic valve replacement market growth. For instance, in May 2025, the U.S. FDA approved Edwards Lifesciences' SAPIEN 3, SAPIEN 3 Ultra, and SAPIEN 3 Ultra RESILIA systems for certain patients with severe aortic stenosis who have no symptoms. The decision expanded the use of TAVR to an earlier stage of the disease and was supported by results from the EARLY TAVR trial.
02 Earlier Intervention Creates New Treatment Opportunities Aortic valve replacement is also moving toward earlier intervention for carefully selected patients rather than waiting until symptoms become severe. This change is encouraging doctors to assess patients more closely and consider factors such as disease progression, age, surgical risk, and overall health when deciding on treatment. As treatment options broaden, the aortic valve replacement market size is benefiting from greater use of both transcatheter and surgical valve replacement. For instance, in April 2025, the FDA approved an expanded indication for Edwards' SAPIEN 3 platform covering patients with asymptomatic severe aortic stenosis who are considered appropriate for TAVR. The decision reflected growing evidence that earlier intervention can provide benefits for selected patients and further expanded the role of transcatheter valve replacement.
01 Growing Burden of Aortic Stenosis and Increasing Adoption of Minimally Invasive Procedures The market is being supported by the growing need to treat severe aortic valve disease, particularly aortic stenosis among older adults. Alongside conventional surgical aortic valve replacement, transcatheter aortic valve replacement is becoming an important treatment option for appropriate patients because it can replace the diseased valve without conventional open-heart surgery. Advances in valve design and delivery systems are helping expand treatment options and supporting aortic valve replacement market demand.
01 High Procedure Costs and Complex Patient Selection The market faces pressure from the high cost of valve replacement procedures, specialized cardiac facilities, imaging requirements, and post-procedure monitoring. Treatment selection is also complex because physicians must consider age, surgical risk, anatomy, life expectancy, valve durability, and other medical conditions when deciding between surgical and transcatheter replacement.
01 Expansion of Valve-in-Valve Procedures and Next-Generation TAVR Technologies The market has significant opportunities as newer transcatheter valves and valve-in-valve procedures expand treatment possibilities for patients who have previously received bioprosthetic or transcatheter valves. Improvements in valve positioning, hemodynamics, delivery systems, and patient-specific treatment planning are shaping important aortic valve replacement market trends.
01 Balancing Minimally Invasive Treatment With Long-Term Valve Durability The market continues to face the challenge of providing less-invasive procedures while ensuring that replacement valves remain safe and effective over the long term. This is particularly important as TAVR is increasingly considered for younger and lower-risk patients, who may live long enough to require another valve intervention. Physicians therefore need to balance faster recovery and lower procedural invasiveness against valve durability and future treatment options.
April 2026 JenaValve Technology announced the commercial launch of the Trilogy® Transcatheter Heart Valve System in the United States following U.S. FDA approval, marking the first commercially available transcatheter valve specifically approved for patients with symptomatic severe aortic regurgitation who are at high surgical risk.
March 2026 JenaValve Technology received U.S. FDA Premarket Approval (PMA) for the Trilogy® Transcatheter Heart Valve System for the treatment of symptomatic severe native aortic regurgitation in patients at high or greater risk for surgical aortic valve replacement, expanding treatment options in the aortic valve replacement market.
January 2026 Edwards Lifesciences announced that it would not proceed with its proposed acquisition of JenaValve Technology following a U.S. court decision, while reaffirming its commitment to advancing transcatheter therapies for aortic valve replacement and aortic regurgitation.
August 2025 The U.S. Federal Trade Commission challenged Edwards Lifesciences' proposed acquisition of JenaValve Technology, citing concerns that the transaction would reduce competition in transcatheter aortic valve replacement (TAVR) devices for aortic regurgitation.